Employing CRISPR-Cas9 to Generate CD133 Synthetic Lethal Melanoma Stem Cells.
Apoptosis
/ genetics
CRISPR-Cas Systems
/ genetics
Caspases
/ metabolism
Cell Line, Tumor
Humans
Melanoma
/ drug therapy
Poly(ADP-ribose) Polymerase Inhibitors
/ pharmacology
Proto-Oncogene Proteins c-akt
/ metabolism
Proto-Oncogene Proteins c-bcl-2
/ metabolism
RNA, Small Interfering
/ pharmacology
Skin Neoplasms
Stem Cells
/ metabolism
bcl-2-Associated X Protein
/ metabolism
Melanoma, Cutaneous Malignant
AKT
CD133
CRISPR/cas9 knockdown
melanoma stem cells
trametinib
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
20 Feb 2022
20 Feb 2022
Historique:
received:
03
02
2022
revised:
17
02
2022
accepted:
18
02
2022
entrez:
26
2
2022
pubmed:
27
2
2022
medline:
9
4
2022
Statut:
epublish
Résumé
Malignant melanoma is a lethal skin cancer containing melanoma-initiating cells (MIC) implicated in tumorigenesis, invasion, and drug resistance, and is characterized by the elevated expression of stem cell markers, including CD133. The siRNA knockdown of CD133 enhances apoptosis induced by the MEK inhibitor trametinib in melanoma cells. This study investigates the underlying mechanisms of CD133's anti-apoptotic activity in patient-derived BAKP and POT cells, harboring difficult-to-treat NRAS
Identifiants
pubmed: 35216449
pii: ijms23042333
doi: 10.3390/ijms23042333
pmc: PMC8877091
pii:
doi:
Substances chimiques
Poly(ADP-ribose) Polymerase Inhibitors
0
Proto-Oncogene Proteins c-bcl-2
0
RNA, Small Interfering
0
bcl-2-Associated X Protein
0
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Caspases
EC 3.4.22.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIEHS NIH HHS
ID : 5 R42 ES026908 03
Pays : United States
Organisme : NIEHS NIH HHS
ID : 1R41ES032435-01
Pays : United States
Organisme : NIGMS NIH HHS
ID : 1R43GM139439-01
Pays : United States
Références
Cancers (Basel). 2019 Oct 03;11(10):
pubmed: 31623313
Int J Oncol. 2017 Jul;51(1):378-388
pubmed: 28534990
Oncogene. 2003 May 19;22(20):3070-5
pubmed: 12789282
Mod Pathol. 2007 Jan;20(1):102-7
pubmed: 17143262
Cancer Res. 2003 Sep 15;63(18):5821-8
pubmed: 14522905
Nature. 2007 Jan 4;445(7123):111-5
pubmed: 17122771
J Invest Dermatol. 2013 May;133(5):1384-7
pubmed: 23389394
Clin Cancer Res. 2015 Apr 1;21(7):1639-51
pubmed: 25589619
Eur J Cancer. 2017 Sep;83:247-257
pubmed: 28756137
Nature. 2008 Dec 4;456(7222):593-8
pubmed: 19052619
Invest New Drugs. 2016 Dec;34(6):740-749
pubmed: 27450049
Int J Oncol. 2012 Nov;41(5):1570-6
pubmed: 22922842
Int J Biochem Cell Biol. 2005 Apr;37(4):715-9
pubmed: 15694831
J Oncol. 2019 Jul 16;2019:6486173
pubmed: 31379943
Nature. 2010 Jan 14;463(7278):191-6
pubmed: 20016485
Artif Cells Nanomed Biotechnol. 2018;46(sup1):1159-1169
pubmed: 29519158
Nat Rev Cancer. 2007 Apr;7(4):246-55
pubmed: 17384580
Nature. 2012 May 09;485(7399):502-6
pubmed: 22622578
Nature. 2004 Nov 18;432(7015):396-401
pubmed: 15549107
Biochem Biophys Res Commun. 2006 Dec 29;351(4):820-4
pubmed: 17097610
Int J Mol Sci. 2017 Jun 15;18(6):
pubmed: 28617309
Oncotarget. 2016 Nov 8;7(45):72758-72766
pubmed: 27602581
Stem Cells. 2012 Oct;30(10):2100-13
pubmed: 22887839
PLoS One. 2012;7(3):e33571
pubmed: 22442699
Cancer Res. 2011 Feb 15;71(4):1474-85
pubmed: 21212411
Cancer Res. 2008 May 1;68(9):3421-8
pubmed: 18451170
Oncotarget. 2017 Feb 21;8(8):12576-12595
pubmed: 28157711
Stem Cells Int. 2016;2016:2087204
pubmed: 27200096
Nature. 2008 Jan 17;451(7176):345-9
pubmed: 18202660
Cancer Res. 2005 Dec 1;65(23):10946-51
pubmed: 16322242
Pharmacol Res. 2016 Sep;111:523-533
pubmed: 27436149
J Invest Dermatol. 2015 Oct;135(10):2475-2483
pubmed: 26016894
Int J Gynecol Cancer. 2008 May-Jun;18(3):506-14
pubmed: 17868344
Cancer Res. 2005 Oct 15;65(20):9328-37
pubmed: 16230395
Carcinogenesis. 2014 Apr;35(4):951-8
pubmed: 24343358
Expert Opin Biol Ther. 2015 May;15(5):735-47
pubmed: 25812921
Cell. 2010 May 14;141(4):583-94
pubmed: 20478252
Oncology (Williston Park). 2009 May;23(6):488-96
pubmed: 19544689
Oncotarget. 2015 Jan 20;6(2):969-78
pubmed: 25504439
Target Oncol. 2016 Jun;11(3):353-61
pubmed: 26566946
Blood. 1997 Dec 15;90(12):5002-12
pubmed: 9389720
Cell Stem Cell. 2007 Sep 13;1(3):313-23
pubmed: 18371365
Clin Cancer Res. 2015 Feb 15;21(4):730-8
pubmed: 25500057
Cancer Res. 2011 Apr 15;71(8):3098-109
pubmed: 21393506
Biochim Biophys Acta. 2016 Apr;1863(4):770-84
pubmed: 26844774
Pigment Cell Melanoma Res. 2020 Mar;33(2):334-344
pubmed: 31549767
PLoS One. 2014 Jul 01;9(7):e101286
pubmed: 24983357
Med Sci Monit. 2020 Apr 10;26:e920957
pubmed: 32273491
Clin Cancer Res. 2012 May 15;18(10):2726-32
pubmed: 22474319
Front Endocrinol (Lausanne). 2016 Oct 26;7:140
pubmed: 27833586
Mol Cancer Res. 2014 Oct;12(10):1509-19
pubmed: 24962318
Pigment Cell Melanoma Res. 2015 May;28(3):307-17
pubmed: 25728708
Pigment Cell Melanoma Res. 2010 Dec;23(6):795-808
pubmed: 20738806
N Engl J Med. 2005 Aug 25;353(8):811-22
pubmed: 16120861
Am J Transl Res. 2018 Jan 15;10(1):304-314
pubmed: 29423015
Nature. 2007 Jan 4;445(7123):106-10
pubmed: 17122772
Lancet Oncol. 2012 Aug;13(8):782-9
pubmed: 22805292
Exp Dermatol. 2015 Feb;24(2):101-7
pubmed: 25363621
Lancet Oncol. 2013 Mar;14(3):249-56
pubmed: 23414587
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4015-20
pubmed: 23431193
Cancer Res. 2004 Oct 1;64(19):7011-21
pubmed: 15466194
Mol Cancer Ther. 2011 Oct;10(10):1829-38
pubmed: 21862685
Oncogene. 2008 Mar 13;27(12):1749-58
pubmed: 17891174
Oncol Rev. 2017 Mar 24;11(1):326
pubmed: 28382191
N Engl J Med. 2012 Nov;367(18):1694-703
pubmed: 23020132
J Pathol. 2008 Jan;214(1):3-9
pubmed: 18067118
Reprod Fertil Dev. 2017 Jun;29(6):1194-1208
pubmed: 27166505
Cancer Treat Rev. 2016 Apr;45:38-45
pubmed: 26975020
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6829-34
pubmed: 23569237
Mol Cancer Res. 2010 Aug;8(8):1105-15
pubmed: 20663862